Restless Legs: Labs, Causes, and Next Steps

What Restless Legs Syndrome Actually Is

RLS, also called Willis-Ekbom disease, is a sensorimotor neurological disorder defined by an urge to move the legs that worsens during rest and improves with movement. Symptoms peak in the evening or at night. The condition is not simply "fidgety legs." It carries a specific neurobiological signature tied to brain iron metabolism and dopaminergic signaling in the basal ganglia.

Population studies place lifetime prevalence between 5% and 15% in European-descent populations, with roughly 2.5% experiencing symptoms severe enough to require medical treatment [1]. The REST (RLS Epidemiology, Symptoms, and Treatment) general population study, surveying 23,052 primary-care patients across five Western European countries and the United States, found that 9.6% of respondents reported RLS-type symptoms, yet only 6.2% met all four diagnostic criteria [2]. Women are 1.5 to 2 times more likely to develop RLS than men, and prevalence rises with age until approximately 65 years before plateauing [1].

A genetic component is well established. First-degree relatives of RLS patients have a 3- to 6-fold increased risk. Genome-wide association studies have identified variants in MEIS1, BTBD9, and MAP2K5 that collectively explain a portion of heritability [3]. These genes influence iron homeostasis and neurodevelopment. Knowing this matters clinically because a strong family history in a patient with a normal ferritin may still respond to iron optimization targeting the brain compartment, where iron levels do not correlate perfectly with peripheral blood markers.

Why You Might Have Restless Legs: The Cause Framework

The urge to move traces back to two interconnected deficits: reduced iron availability in the central nervous system and downstream disruption of dopamine synthesis. Iron serves as a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine production. When brain iron drops, dopaminergic tone in the A11 diencephalospinal pathway falls, and sensory gating breaks down [4].

Primary (idiopathic) RLS accounts for roughly 40 to 60% of cases. These patients typically have a positive family history, symptom onset before age 45, and slow progression.

Secondary RLS arises from identifiable triggers:

• Iron deficiency. The single largest reversible cause. A 2019 systematic review in Sleep Medicine Reviews (N=10 controlled trials) found that IV ferric carboxymaltose reduced IRLS severity scores by a mean of 7.8 points versus placebo when baseline ferritin was below 75 ng/mL [5].
• End-stage renal disease. Prevalence in dialysis patients ranges from 20 to 57%, driven by impaired erythropoiesis and uremic toxins [6].
• Pregnancy. Up to 26% of pregnant women develop RLS, most commonly in the third trimester, with resolution within four weeks postpartum in the majority of cases [7].
• Peripheral neuropathy. Diabetes, B12 deficiency, and small-fiber neuropathy frequently co-occur with RLS.
• Medications. Antidepressants (SSRIs, SNRIs, mirtazapine), antihistamines (diphenhydramine), and dopamine-blocking antiemetics (metoclopramide) can trigger or worsen RLS.

The Lab Panel Your Clinician Should Order

No blood test diagnoses RLS on its own. Diagnosis is clinical. Labs exist to identify treatable causes and rule out mimics. A targeted panel, not a shotgun approach, gives the best return.

Tier 1 (order for every suspected RLS patient):

| Test | Why It Matters | Action Threshold | |------|---------------|-----------------| | Serum ferritin | Reflects total-body iron stores; correlates with brain iron on MRI [8] | Treat if <75 ng/mL (IRLSSG guideline) | | Transferrin saturation (TSAT) | Detects functional iron deficiency even if ferritin is normal-range | Treat if <20% | | CBC with differential | Screens for anemia, macrocytosis (B12/folate), microcytosis (iron) | Interpret alongside ferritin |

Tier 2 (order based on clinical suspicion):

| Test | When to Order | |------|--------------| | TSH | Symptoms of thyroid dysfunction or age over 50 | | HbA1c or fasting glucose | Risk factors for diabetes or signs of neuropathy | | Comprehensive metabolic panel | Renal impairment suspected | | Vitamin B12 and folate | Macrocytic anemia, neuropathy symptoms, or vegan diet | | Magnesium | Diuretic use, chronic PPI therapy, or muscle cramping |

The 2024 IRLSSG consensus update reaffirmed that a ferritin threshold of 75 ng/mL (not the standard lab reference range of 12 to 15 ng/mL) should trigger iron repletion in RLS patients [9]. This distinction catches many clinicians off guard. A ferritin of 40 ng/mL, flagged as "normal" on a standard lab report, is actually below the treatment threshold for RLS.

Dr. Richard Allen, a lead author of the IRLSSG consensus guidelines and professor at Johns Hopkins, has stated: "A ferritin of 50 in a patient with RLS is not normal. The brain's iron needs are higher than what peripheral markers suggest, and we treat to a target, not to a reference range."

How RLS Is Diagnosed: The Four Essential Criteria

The International RLS Study Group established four criteria that must all be present [10]. No polysomnography is required for typical cases.

1. An urge to move the legs, usually accompanied by uncomfortable sensations (described as crawling, pulling, throbbing, or aching).
2. Symptoms begin or worsen during rest or inactivity, such as lying down or sitting.
3. Symptoms are partially or totally relieved by movement, such as walking or stretching, for at least as long as the activity continues.
4. Symptoms occur exclusively or predominantly in the evening or night, not solely because that is when the patient is at rest.

A fifth supportive criterion, the presence of periodic limb movements during sleep (PLMS), is found in over 80% of RLS patients but is not required for diagnosis. An overnight polysomnogram or actigraphy becomes useful when the diagnosis is uncertain, when sleep apnea is a competing explanation, or when PLMS index is needed to guide treatment intensity.

The IRLSSG Severity Scale (IRLS), a 10-question validated instrument with a maximum score of 40, classifies disease as mild (1 to 10), moderate (11 to 20), severe (21 to 30), or very severe (31 to 40) [10]. Tracking IRLS scores over time gives an objective measure of treatment response.

Conditions That Mimic RLS

Several disorders produce similar leg discomfort. Misdiagnosis delays proper treatment.

Nocturnal leg cramps cause sudden, painful muscle contractions rather than an urge to move. They resolve spontaneously and lack the circadian pattern of RLS. Peripheral neuropathy produces burning, tingling, and numbness that persist regardless of movement and do not follow the evening-predominant pattern. Akathisia, most often drug-induced, creates a whole-body inner restlessness not confined to the legs and unrelated to a circadian rhythm. Positional discomfort from arthritis or venous insufficiency improves with position change, not with the specific rhythmic movement that relieves RLS.

A careful history distinguishing the urge-to-move component from pure pain or cramping eliminates most mimics within a 10-minute clinical interview.

First-Line Treatment: Iron Repletion

If ferritin is below 75 ng/mL or TSAT is below 20%, iron repletion is the first intervention, and it should happen before prescribing any RLS-specific medication.

Oral iron: Ferrous sulfate 325 mg (65 mg elemental iron) taken every other day on an empty stomach with vitamin C 200 mg improves absorption. A 2020 study in the Lancet confirmed that alternate-day dosing produces equal or superior fractional absorption compared to daily dosing while reducing GI side effects [11]. Recheck ferritin at 12 weeks. Goal: ferritin above 100 ng/mL.

IV iron: Preferred when oral iron fails, ferritin is below 30 ng/mL, or the patient cannot tolerate oral formulations. Ferric carboxymaltose 750 mg given as two infusions one week apart is a common protocol. A randomized controlled trial (N=116) published in Sleep Medicine found that a single 1,000 mg dose of ferric carboxymaltose reduced IRLS scores by 40% at 12 weeks versus 15% with placebo [5]. Onset of benefit typically occurs 4 to 6 weeks after infusion.

Dr. Christopher Earley, a neurologist at Johns Hopkins and a principal investigator in RLS iron trials, has noted: "We see patients who have been on dopamine agonists for years with worsening symptoms, and their ferritin is 35. Correcting the iron first would have prevented the entire cascade of augmentation."

Pharmacologic Treatment Beyond Iron

When symptoms persist after iron optimization (ferritin confirmed above 75 ng/mL) or when RLS is moderate to severe at presentation, pharmacotherapy is appropriate. The 2024 IRLSSG guidelines rank treatments by efficacy and long-term safety [9].

Alpha-2-delta ligands (first-line):

Gabapentin enacarbil (Horizant) 600 mg taken at 5 PM is FDA-approved for moderate-to-severe RLS. The 12-week PIVOT trial (N=325) showed a mean IRLS score reduction of 13.2 points versus 8.8 for placebo (P<0.001) [12]. Standard gabapentin 300 to 900 mg nightly and pregabalin 150 to 450 mg nightly are off-label alternatives with similar mechanism. These agents carry no augmentation risk.

Common side effects include dizziness, somnolence, and peripheral edema. Dose reduction is needed in renal impairment (CrCl <60 mL/min).

Dopamine agonists (second-line, with caution):

Pramipexole 0.125 to 0.5 mg and ropinirole 0.25 to 4 mg provide rapid symptom relief but carry a 40 to 70% long-term augmentation rate. Augmentation, the paradoxical worsening of RLS with continued dopamine agonist use, is the single biggest pitfall in RLS management. Symptoms spread to the arms, onset shifts earlier in the day, and higher doses provide diminishing relief [13]. The IRLSSG now recommends avoiding dopamine agonists as initial therapy in most patients.

The rotigotine transdermal patch (Neupro) 1 to 3 mg/24 hr has a somewhat lower augmentation rate (estimated 10 to 20% over five years) due to continuous drug delivery, but it remains second-line [14].

Third-line and refractory options:

Low-dose opioids (oxycodone 5 to 15 mg extended-release nightly) demonstrated sustained efficacy over 12 months in the randomized, placebo-controlled trial by Trenkwalder et al. (N=304) with an IRLS score reduction of 10.6 points versus 5.8 for placebo [15]. These are reserved for patients who fail alpha-2-delta ligands and iron optimization due to abuse liability and regulatory constraints.

When to Worry and When to See a Specialist

Most RLS is a nuisance. Some signals demand prompt evaluation.

Red flags requiring referral:

• Symptoms unresponsive to 8 weeks of first-line therapy at adequate doses
• Suspected augmentation (symptoms spreading, earlier onset, dose escalation without benefit)
• Diagnostic uncertainty after initial workup (symptoms don't fit all four IRLSSG criteria)
• RLS onset in a child or adolescent (prevalence 2 to 4%, often misdiagnosed as growing pains or ADHD)
• Severe sleep disruption causing daytime impairment, depression, or suicidal ideation

Who to see: A sleep medicine specialist or a neurologist with RLS expertise. A referral to hematology is appropriate if ferritin remains below 30 ng/mL despite oral iron or if an underlying hematologic condition is suspected.

Non-Pharmacologic Strategies That Have Evidence

Not every intervention requires a prescription. Several behavioral and lifestyle modifications have shown measurable benefit in controlled studies.

Pneumatic compression. The 2014 randomized trial by Lettieri et al. (N=35) using sequential pneumatic leg compression for one hour before bed showed a 36% reduction in IRLS scores at 4 weeks compared to sham [16]. The FDA cleared the Restiffic foot wrap for RLS based on a similar mechanism of counter-stimulation.

Exercise. A 2019 meta-analysis in Sleep Medicine Reviews pooling 5 RCTs (N=219) found that aerobic exercise 3 times per week for 12 weeks reduced IRLS scores by a standardized mean difference of 0.78 (95% CI 0.37 to 1.19, P<0.001), roughly equivalent to the effect size of low-dose gabapentin [17]. Timing matters: vigorous exercise within two hours of bedtime may worsen symptoms in some patients.

Sleep hygiene modifications. Consistent sleep-wake times, cool bedroom temperature (65 to 68°F), and avoidance of caffeine after noon are not curative but reduce symptom triggering in patients with mild RLS. Alcohol worsens RLS in dose-dependent fashion and should be minimized.

Trigger avoidance. Antihistamines containing diphenhydramine (Benadryl, ZzzQuil) are among the most common OTC medications that worsen RLS. Patients should be counseled to use non-sedating antihistamines like cetirizine or loratadine as alternatives.

Building Your Personal Action Plan

A stepwise approach prevents both under-treatment and unnecessary medication exposure.

Step 1: Get the right labs. Request serum ferritin, TSAT, CBC, and any tier-2 labs based on your clinical picture. Ask your clinician to interpret ferritin against the 75 ng/mL RLS threshold, not the standard reference range.

Step 2: Correct iron deficiency first. Oral iron every other day for 12 weeks, then recheck. Switch to IV iron if ferritin has not risen above 75 ng/mL or if GI intolerance limits adherence.

Step 3: Audit your medication list. Discontinue or substitute SSRIs, antihistamines, and dopamine blockers where clinically feasible (always in coordination with the prescribing clinician).

Step 4: Add non-pharmacologic measures. Moderate aerobic exercise three times per week, pneumatic compression if available, and strict avoidance of late caffeine and alcohol.

Step 5: If symptoms remain moderate to severe (IRLS score above 15) after 8 to 12 weeks of iron optimization, start gabapentin enacarbil 600 mg at 5 PM or pregabalin 150 mg nightly, titrating based on response and tolerability.

The ferritin recheck at 12 weeks after starting iron repletion is the single most skipped step in RLS management and the one most likely to change outcomes.